Does the ProQR (PRQR) Form 4 show any share sales by Bart Filius?

No share sales are shown for Bart Filius in this Form 4. The transaction summary reflects one open-market purchase of 150,000 Ordinary Shares and indicates zero reported sales, gifts, tax withholdings, or derivative exercises in this particular filing.

Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Bart Filius reported an open-market purchase of Ordinary Shares. On the reported date, he bought 150,000 Ordinary Shares at a price of $1.54 per share. Following this transaction, his directly held position in ProQR totals 150,000 Ordinary Shares.

Insider Trade Summary

Net Buyer: 150,000 shares ($231,000)

Net Buy 1 txn

Insider Filius Bart

Role null

Bought 150,000 shs ($231K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	150,000	$1.54	$231K

Holdings After Transaction: Ordinary Shares — 150,000 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 150,000 shares Purchase price: $1.54 per share Shares owned after transaction: 150,000 shares +2 more

5 metrics

Shares purchased 150,000 shares Ordinary Shares bought in open-market transaction

Purchase price $1.54 per share Transaction price for Ordinary Shares

Shares owned after transaction 150,000 shares Total directly held Ordinary Shares following purchase

Buy transactions count 1 transaction Number of buy transactions in this Form 4

Net buy/sell direction net-buy of 150,000 shares Transaction summary for reported period

Key Terms

Ordinary Shares, open-market purchase, Form 4, direct ownership, +1 more

5 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

non-derivative financial

"transaction_type: "non-derivative""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:01 PM Accepted by SEC EDGAR 06/30/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Filius Bart

(Last)

(First)

(Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN

2333 CK

(City)

(State)

(Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/26/2026		P		150,000	A	$1.54	150,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ProQR (PRQR) director Bart Filius report?

Director Bart Filius reported an open-market purchase of ProQR Ordinary Shares. He bought 150,000 Ordinary Shares at a price of $1.54 per share, and after this transaction he directly holds 150,000 Ordinary Shares in ProQR Therapeutics N.V.

How many ProQR (PRQR) shares did Bart Filius buy in this Form 4 filing?

Bart Filius bought 150,000 Ordinary Shares of ProQR. The Form 4 shows this as a non-derivative, open-market purchase, and his total directly owned holdings after the transaction are 150,000 Ordinary Shares according to the reported figures.

At what price were the ProQR (PRQR) shares purchased by Bart Filius?

The shares were purchased at $1.54 per Ordinary Share. This price is listed in the Form 4 as the transaction price per share for the 150,000 Ordinary Shares acquired in the open-market purchase reported for director Bart Filius.

What is Bart Filius’s total ProQR (PRQR) ownership after this reported trade?

After this transaction, Bart Filius directly owns 150,000 Ordinary Shares of ProQR. The Form 4 specifies this figure as the total number of shares held following the reported open-market purchase, with ownership characterized as direct rather than indirect.